Literature DB >> 23403911

Medication use in US youth with mental disorders.

Kathleen R Merikangas1, Jian-ping He, Judith Rapoport, Benedetto Vitiello, Mark Olfson.   

Abstract

OBJECTIVE: To evaluate the prevalence, demographic and clinical correlates, and specificity of classes of psychotropic medications indicated for mental disorders.
DESIGN: Cross-sectional survey.
SETTING: Direct household interviews of combined household and school samples representative of the general population of adolescents in the United States. PARTICIPANTS: Ten thousand one hundred twenty-three adolescents aged 13 to 18 years who participated in the National Comorbidity Survey Adolescent Supplement. MAIN EXPOSURES: Diagnostic and Statistical Manual of Mental Disorders (Fourth Edition) (DSM-IV) mental disorders and neurodevelopmental disorders. OUTCOME MEASURE: Psychotropic medication use in the past 12 months.
RESULTS: Among youth with any DSM-IV mental disorder, 14.2% reported that they had been treated with a psychotropic medication in the past 12 months. Strong associations emerged between specific disorders and classes of medications with evidence for efficacy. Antidepressants were most frequently used among those with primary mood disorders (14.1%); stimulant use was most common among those with attention-deficit/hyperactivity disorder (20.4%); and antipsychotic use was infrequent and mostly seen among those with serious developmental disorders. Less than 2.5% of adolescents without a 12-month mental disorder had been prescribed psychotropic medications, and most had evidence of psychological distress or impairment reflected in a previous mental disorder, subthreshold condition, or developmental disorder. Appropriate medication use was significantly more frequent among those in treatment in the mental health specialty sector than general medicine or other settings.
CONCLUSIONS: These findings challenge recent concerns over widespread overmedication and misuse of psychotropic medications in US youth. In fact, these data highlight the need for greater recognition and appropriate treatment of youth with mental health disorders.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23403911     DOI: 10.1001/jamapediatrics.2013.431

Source DB:  PubMed          Journal:  JAMA Pediatr        ISSN: 2168-6203            Impact factor:   16.193


  26 in total

1.  Using stimulants for attention-deficit/hyperactivity disorder: clinical approaches and challenges.

Authors:  Jonathan R Stevens; Timothy E Wilens; Theodore A Stern
Journal:  Prim Care Companion CNS Disord       Date:  2013-03-28

2.  Psychiatric disorders in 22q11.2 deletion syndrome are prevalent but undertreated.

Authors:  S X Tang; J J Yi; M E Calkins; D A Whinna; C G Kohler; M C Souders; D M McDonald-McGinn; E H Zackai; B S Emanuel; R C Gur; R E Gur
Journal:  Psychol Med       Date:  2013-09-09       Impact factor: 7.723

Review 3.  Primary Pediatric Care Psychopharmacology: Focus on Medications for ADHD, Depression, and Anxiety.

Authors:  Jeffrey R Strawn; Eric T Dobson; Lisa L Giles
Journal:  Curr Probl Pediatr Adolesc Health Care       Date:  2016-12-30

4.  Identifying the gaps between science, policies, services, and the needs of youths affected by mental disorders.

Authors:  Guilherme V Polanczyk
Journal:  Eur Child Adolesc Psychiatry       Date:  2014-12       Impact factor: 4.785

5.  A Critique of Sociocultural Values in PBIS.

Authors:  Alyssa N Wilson
Journal:  Behav Anal Pract       Date:  2015-04-28

6.  Prevalence and Correlates of Hypersomnolence Symptoms in US Teens.

Authors:  Bhanu Prakash Kolla; Jian-Ping He; Meghna P Mansukhani; Suresh Kotagal; Mark A Frye; Kathleen R Merikangas
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2018-10-30       Impact factor: 8.829

7.  Interprovincial Variation in Antipsychotic and Antidepressant Prescriptions Dispensed in the Canadian Pediatric Population.

Authors:  Nikita Arora; Sandra Knowles; Tara Gomes; Muhammad M Mamdani; David N Juurlink; Corine Carlisle; Mina Tadrous
Journal:  Can J Psychiatry       Date:  2016-07-10       Impact factor: 4.356

8.  Children's Clinical Complexity Drives Psychiatric Medication Costs to Rival Hospital Costs.

Authors:  Charley Huffine; Debra Srebnik; Laurie Sylla; Eric Trupin; Terry Lee
Journal:  J Behav Health Serv Res       Date:  2017-04       Impact factor: 1.505

9.  The diminished pipeline for medications to treat mental health and substance use disorders.

Authors:  Peggy L O'Brien; Cindy Parks Thomas; Dominic Hodgkin; Katharine R Levit; Tami L Mark
Journal:  Psychiatr Serv       Date:  2014-11-17       Impact factor: 3.084

Review 10.  Common Factors in Pediatric Psychiatry: A Review of Essential and Adjunctive Mechanisms of Treatment Outcome.

Authors:  Alessandro S De Nadai; Marc S Karver; Tanya K Murphy; Mark A Cavitt; Jeffrey L Alvaro; Michael Bengtson; Saundra Stock; Andrew C Rakhshani; Eric A Storch
Journal:  J Child Adolesc Psychopharmacol       Date:  2016-04-29       Impact factor: 2.576

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.